LALPATHLAB - Swing Trade Analysis with AI Signals
Back to List📊 Swing Trade Rating: 3.9
| Stock Code | LALPATHLAB | Market Cap | 22,908 Cr. | Current Price | 1,367 ₹ | High / Low | 1,771 ₹ |
| Stock P/E | 43.1 | Book Value | 148 ₹ | Dividend Yield | 0.88 % | ROCE | 29.4 % |
| ROE | 23.1 % | Face Value | 10.0 ₹ | DMA 50 | 1,393 ₹ | DMA 200 | 1,443 ₹ |
| Chg in FII Hold | -3.11 % | Chg in DII Hold | 2.17 % | PAT Qtr | 141 Cr. | PAT Prev Qtr | 113 Cr. |
| RSI | 44.7 | MACD | 9.36 | Volume | 3,01,935 | Avg Vol 1Wk | 2,27,566 |
| Low price | 1,272 ₹ | High price | 1,771 ₹ | PEG Ratio | 1.94 | Debt to equity | 0.08 |
| 52w Index | 19.1 % | Qtr Profit Var | -4.92 % | EPS | 30.3 ₹ | Industry PE | 34.6 |
Analysis: Dr. Lal PathLabs (LALPATHLAB) shows strong fundamentals but weak technical momentum. Current price (1,367 ₹) is below both DMA 50 (1,393 ₹) and DMA 200 (1,443 ₹), indicating short-term weakness. RSI at 44.7 suggests the stock is approaching oversold territory, while MACD (9.36) signals mild bullishness. ROCE (29.4%) and ROE (23.1%) are strong, supported by low debt-to-equity (0.08). Quarterly PAT improved (141 Cr. vs 113 Cr.), though profit variation (-4.92%) raises caution. Valuation is slightly stretched with P/E of 43.1 compared to industry PE of 34.6, and PEG ratio of 1.94 suggests moderate growth potential. EPS of 30.3 ₹ adds earnings visibility.
Optimal Entry Price: Around 1,340–1,350 ₹ (near support zone).
Exit Strategy if Holding: Consider booking profits near 1,420–1,450 ₹ unless momentum sustains above 1,460 ₹ resistance.
✅ Positive
- Strong ROCE (29.4%) and ROE (23.1%).
- Low debt-to-equity ratio (0.08) ensures financial stability.
- Quarterly PAT growth (141 Cr. vs 113 Cr.).
- DII holdings increased (+2.17%), showing domestic investor confidence.
⚠️ Limitation
- Stock trading below DMA 50 and DMA 200 indicates weak technicals.
- High P/E (43.1) compared to industry average (34.6).
- Quarterly profit variation (-4.92%) raises caution.
- FII holdings decreased (-3.11%), showing reduced foreign interest.
📰 Company Negative News
- No major negative news reported, but weak technicals and reduced foreign interest are concerns.
🌟 Company Positive News
- Strong efficiency metrics (ROCE and ROE).
- Quarterly PAT growth supports investor sentiment.
- Domestic institutional investors increased their stake.
🏭 Industry
- Industry P/E at 34.6 suggests Lal PathLabs trades at a premium.
- Diagnostics and healthcare sector remains resilient with steady demand growth.
📌 Conclusion
Lal PathLabs is a moderate candidate for swing trading. Entry around 1,340–1,350 ₹ offers a safer risk-reward setup, while exit near 1,420–1,450 ₹ is advisable unless momentum sustains above 1,460 ₹. Strong fundamentals and domestic investor support are positives, but weak technicals and reduced foreign interest warrant cautious optimism.
Would you like me to expand this with a technical chart outlook, peer comparison, or sector growth analysis?